"This is not like the old days," CNBC's Jim Cramer says about the Greek-EU standoff.» Read More
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
With the wipeout in growth stocks, many investors turned their attention to big-cap and value names, and the trend is expected to continue.
CNBC’s Jim Cramer says money should flow from stocks with heavy exposure to Ukraine and China into domestic retailers with strong growth.
New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.
Some of Tuesday's midday movers:
Some of Monday's midday movers:
U.S. bonds pushed higher on Friday, after disappointing manufacturing data from both the U.S. and China revived the safe haven bid for Treasurys.
Friday's midday movers:
U.S. stock prices could continue to correct, but it's too soon to say whether this is the big one.
CNBC's Jim Cramer offers some simple advice on how to deal with the Wall Street selloff.
U.S. stock index futures pointed to another steep loss on Friday, with European and Asian shares trading lower.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
With uncertainty rampant in the market, pros will be watching earnings very closely. Which results matter most to Cramer?
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
The "Fast Money" traders share their final trades of the day.
Some of Wednesday's midday movers:
Companies are making headlines before the bell Thursday.
AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture in a deal worth $4.1 billion.
Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.
Some of Friday's midday movers: